Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2489)	5/3/2005 2:16:33 AM
From: SnowShredder	Respond to of 12215

Thanks Rick. I hope all is well with you. I'm still in LA, just sorted thru a crate of my mail(not to mention the 2 other crates I went thru last time I was home), that my Dad dropped off on his visit to LA...so much junk mail(good thing for competent secretarys ;). Maybe I've misunderstood the private placement, but I found it interesting that the closing price of today for Macropore was @ $3.60 when an investor is paying $10 a share for 1.1 million shares, with an option to buy another 2.2 million shares @ $10 that expires in less than 2 years. That is just a slight price difference ;) I wonder how they derived that price? Maybe, when I find some time & if I remember, I'll give Marc a call to find out more details, or I'll just cruise to SD and stop by for a visit. Best of Luck, SS

To: scaram(o)uche who wrote (2489)	5/3/2005 2:10:30 PM
From: keokalani'nui	Read Replies (2) \| Respond to of 12215

Press Release Source: Rodman & Renshaw, LLC Rodman & Renshaw Adds Two Prominent Analysts to Its Life-Sciences Research Team Tuesday May 3, 1:45 pm ET NEW YORK--(BUSINESS WIRE)--May 3, 2005--Rodman & Renshaw, LLC today announces the appointment of two prominent healthcare analysts to its life-sciences research team. Michael G. King, Jr., who is recognized among his peers as one of the sell-side's most authoritative voices on the life-sciences industry, joins Rodman & Renshaw after nearly three years as a managing director and senior biotechnology analyst at Banc of America Securities LLC (BofA). During his tenure at BofA, Mr. King was ranked #11 in the 2004 Institutional Investor All-Star Poll, and also ranked as runner-up in the hedge fund portion of the survey. Prior to BofA, Mr. King served as a managing director and senior biotechnology analyst at Robertson Stephens. He served in a similar capacity for three years at Vector Securities International. Mr. King has also been affiliated with Kidder, Peabody, Hambrecht and Quist, Alex Brown & Sons, and D. Blech and Co. At Rodman & Renshaw, Mr. King will cover a wide variety of life-sciences companies, ranging from micro-cap opportunities to the large-cap industry leaders. Matthew Murray, Ph.D., CFA, one of the few Wall Street analysts with extensive experience on both the money management and brokerage sides of the industry, also joined the research team at Rodman & Renshaw. Dr. Murray was most recently a portfolio manager and healthcare analyst at Alliance Capital, a position he held for the past six years. Prior to joining Alliance, he was a senior biotechnology analyst at Lehman Brothers and also served in similar capacities at Union Bank of Switzerland, and Alex Brown. Before starting a career on Wall Street, Dr. Murray worked at the National Academy of Sciences and as a staff member in the United States Senate. He graduated first in his class from UC Berkeley to receive his Ph.D. in BioPhysics and has also earned a CFA degree. At Rodman & Renshaw, Dr. Murray will cover a wide variety of life-sciences companies, ranging from micro-cap opportunities to the large-cap industry leaders. John Borer, President of Rodman & Renshaw, stated, "We are very pleased with the addition of these two renowned analysts in the life-sciences sector to our already well-regarded team of analysts. The collective experience that Michael and Matthew bring to the table will further enhance Rodman & Renshaw's preeminence in the life-sciences sectors."